Neuroprotective effect of diosgenin in 6-hydroxydopamine-induced model of Parkinson’s disease in the rat

Authors

Abstract

Background and Objective: Parkinson's disease is one the most common neurodegenerative diseases clinically diagnosed by movement disorders such as slowness of movement, muscle stiffness, tremor at rest and personality disorder. The goal of this study was to examine the impact of diosgenin with antioxidant and neuroprotective effects on a rat model of Parkinson's disease induced by 6-hydroxydopamine.
 
Materials and Methods: Forty male Wistar rats were divided into four groups. 1-sham, 2-sham treated with diosgenin (100 mg/kg) 3- The group microinjected with 6-hydroxydopamine (6-OHDA) and 4- 6-OHDA group treated with diosgenin. Rats received diosgenin by gavage before surgery for 1 week. At the end of this period, the experimental model of Parkinson's disease was induced by unilateral injection of 6-OHDA into the striatum. Rotational behavior was studied after the surgery. Malondialdehyde  (MDA), glutathione  (GSH), catalase, nitrite and glial fibirally acidic protein (GFAP) were measured in the homogenate. Also, nigral neurons were counted and compared using Nissl staining.
 
Results: There was a significant reduction of rotations in diosgenin-pretreated 6-OHDA-lesioned rats as compared to untreated 6-OHDA group. In addition, pretreatment with diosgenin in 6-OHDA-lesioned group significantly prevented the reduction of neurons in the substantia nigra pars compacta as compared to the untreated group (P<0.05). Also, diosgenin pretreatment decreased the level of GFAP and MDA in the brain homogenate (P<0.01) and increased level of glutathione (GSH) (P<0.05). There was also no significant change regarding nitrite and catalase.
 
Conclusion: Diosgenin pretreatment improved motor behavior and asymmetry in 6-OHDA-lesioned rats and protected substantia nigra pars compacta neurons and its effect is mediated via attenuation of oxidative stress and astrogliosis.

Keywords

References

1. Skodda S, Visser W, Schlegel U. Gender-related patterns of dysprosody in Parkinson disease and correlation between speech variables and motor symptoms. Journal of Voice 2011;25 (1):76-82. 2. Ungprasert P, Srivali N, Thongprayoon C. Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis. Parkinsonism & Related Disorders 2015;21 (10):1238-42. 3. Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, et al. Prodromal markers in parkinson's disease: limitations in longitudinal studies and lessons learned. Frontiers in Aging Neuroscience 2016;8:147. 4. Lutz SG, Holmes JD, Ready EA, Jenkins ME, Johnson AM. Clinical presentation of anxiety in Parkinson's disease: a scoping review. OTJR: Occupation, Participation and Health 2016;36 (3):134-47. 5. Mariani E, Frabetti F, Tarozzi A, Pelleri MC, Pizzetti F, Casadei R. Meta-analysis of parkinson's disease transcriptome data using tram software: whole substantia nigra tissue and single dopamine neuron differential gene expression. PloS One 2016;11 (9):e0161567. 6. Binks S, Dobson R. Risk factors, epidemiology and treatment strategies for metabolic bone disease in patients with neurological disease. Current Osteoporosis Reports 2016; 14(5):199-210. 7. Duarte IS, Holanda Gdo N, Martins MA. Laryngeal electromyography and acoustic voice analysis in Parkinson's disease: a comparative study. Brazilian Journal of Otorhinolaryngology 2010;76 (1):40-3. 8. Pupillo E, Cricelli C, Mazzoleni F, Cricelli I, Pasqua A, Pecchioli S, et al. Epidemiology of Parkinson's disease: a population-based study in primary care in Italy. Neuroepidemiology 2016;47 (1):38-45. 9. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Time trends in the incidence of Parkinson disease. JAMA Neurology 2016;73 (8):981-9. 10. de Araujo DF, de Melo Neto AP, Oliveira IS, Brito BS, de Araujo IT, Barros IS, et al. Small (autonomic) and large fiber neuropathy in Parkinson disease and parkinsonism. BMC Neurology 2016;16:139. 11. Hong H, Kim BS, Im HI. Pathophysiological Role of Neuroinflammation in neurodegenerative diseases and psychiatric disorders. International Neurology Journal 2016;20 (Suppl 1):S2-7. 12. Main BS, Zhang M, Brody KM, Ayton S, Frugier T, Steer D, et al. Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease. Glia 2016;64 (9):1590-604.
Daneshvar Medicine
Volume 25, Issue 2 - Serial Number 129
July and August 2017
Pages 87-98

Files

Share

How to cite

Statistics